Friday, October 30, 2015 - 08:30

Clinigen Group plc (AIM: CLIN, "Clinigen" or the "Group"), the global specialty pharmaceuticals business, has today completed the acquisition of Link Healthcare Private Limited ("Link") which was announced on 22 September 2015 (the "Acquisition").

As a result of the completion of the Acquisition (“Completion”), 3,102,558 new ordinary shares in the Group have been allotted, credited as fully paid, to the vendors of Link.

Accordingly, the Group now has in issue 114,553,730 ordinary shares of 0.1p each, with voting rights. Clinigen does not hold any shares in treasury. This figure of 114,553,730 ordinary shares may be used by shareholders in Clinigen to determine if they are required to notify their interest in, or a change in their interest in, Clinigen under the Financial Conduct Authority's Disclosure and Transparency Rules.

Peter George, Chief Executive Officer of Clinigen, said:
“The completion of this strategic acquisition strengthens our international distribution network across the AAA region - Asia, Africa and Australasia. We welcome Link to the Group and look forward to being even better placed to directly supply much needed, but not always licensed, medicines into the growing ‘pharmerging’ markets.

“Together, our combined entity further supports our underlying philosophy of getting the right drug to the right patient at the right time regardless of the location anywhere in the world.”

Upon Completion, John Bacon, Group Chairman and Founder of Link, was appointed to the Clinigen Board as a Non-Executive Director. Please see separate announcement.

-Ends-

 

Contact Details

Clinigen Group plc
Peter George, Group Chief Executive Officer
Shaun Chilton, Group Deputy Chief Executive Officer
Martin Abell, Group Chief Financial Officer
Tel: +44 (0) 1283 495010

Numis Securities Limited
Michael Meade/Freddie Barnfield (Nominated Adviser)
James Black/Tom Ballard  (Corporate Broking)
Tel: +44 (0) 20 7260 1000

Peel Hunt LLP - Joint Broker 
James Steel/Jock Maxwell Macdonald
Tel: +44 (0) 20 7418 8900

Instinctif Partners 
Melanie Toyne-Sewell/Jayne Crook/Emma Barlow
Tel: +44 (0) 20 7457 2020
Email: clinigen@instinctif.com

 

Notes to Editors

About Clinigen Group

Clinigen Group is a global pharmaceutical and services company with a unique business model dedicated to delivering the right drug to the right patient at the right time. The Group consists of four synergistic businesses that provide medicines to patients with unmet medical need; Clinigen CTS manages the supply of commercial medicines for clinical trials; Idis Managed Access runs early access programs for Clinigen’s own and other companies' portfolios; Idis Global Access works directly with healthcare providers to enable ethical compliant access to unlicensed medicines and Clinigen SP acquires and markets our own portfolio of hospital only niche medicines.

Clinigen is the global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need.

For more information, please visit www.clinigengroup.com.

Back to News